logo

INFY vs SUNPHARMA: Stock Comparison

INFOSYS vs SUN PHARMACEUTICAL IND LUpdated 23 Oct 26, 4:08 PM ISTNSE & company filings

INFOSYS is the larger company by market capitalisation. INFOSYS shows a lower P/E, a higher ROE and a higher dividend yield, while SUN PHARMACEUTICAL IND L shows faster revenue growth and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

INFY leads 7; SUNPHARMA leads 4 of 13

Not a rating
These companies operate in different sectors (Information Technology vs Healthcare). Valuation and leverage norms differ across sectors, so cross-sector ratio comparisons can mislead — compare each against its own sector peers too.

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

INFYSUNPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹4.69 L Cr
₹4.18 L Cr
P/E RatioINFY has the lower reading
15.23x ✓
34.58x
P/B RatioINFY has the lower reading
4.73x ✓
5x
EPSINFY has the higher reading
₹19.15 ✓
₹12.06
Book ValueContext only
₹229.93
₹349.6
Dividend YieldINFY has the higher reading
4.16% ✓
0.92%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
INFY is the larger company
₹4.69 L Cr vs ₹4.18 L Cr
P/E Ratio
INFY has a lower P/E
15.23x vs 34.58x
P/B Ratio
INFY has a lower P/B
4.73x vs 5x
EPS
INFY has higher earnings per share
₹19.15 vs ₹12.06
Dividend Yield
INFY has a higher dividend yield
4.16% vs 0.92%
Revenue Growth (TTM YoY)
SUNPHARMA has faster revenue growth
12.8% vs 6.6%
EPS Growth (TTM YoY)
SUNPHARMA has faster EPS growth
25.6% vs 11.8%
ROE
INFY has a higher ROE
31.59% vs 13.72%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricINFYSUNPHARMA
SectorInformation TechnologyHealthcare
IndustryComputers - Software & ConsultingPharmaceuticals

Price

MetricINFYSUNPHARMA
Live Price₹1,153.8₹1,748
Day Change0.04%-0.57%
Volume3.3 Cr10.65 L
52-Week High₹1,728₹2,046.9
52-Week Low₹980.4₹1,583.7
Distance from 52W High-33.23%-14.6%

Valuation

MetricINFYSUNPHARMA
Market Cap₹4.69 L Cr₹4.18 L Cr
P/E Ratio15.23x34.58x
P/B Ratio4.73x5x
EPS₹19.15₹12.06
Book Value₹229.93₹349.6
Dividend Yield4.16%0.92%

Growth

MetricINFYSUNPHARMA
Revenue Growth (TTM YoY)6.6%12.8%
EPS Growth (TTM YoY)11.8%25.6%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricINFYSUNPHARMA
ROE31.59%13.72%
ROCE41.89%15.16%
Net Margin16.44%18.56%
Operating Margin22.62%26.44%
Debt to Equity0x0.05x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricINFYSUNPHARMA
Promoter Holding13.82%▼ 0.56 pp52.68%▼ 1.8 pp
FII Holding27.09%▼ 1.36 pp14.36%▼ 0.17 pp
DII Holding42.96%▼ 0.42 pp22.27%▲ 0.09 pp
Public Holding15.89%▲ 2.36 pp10.7%▲ 1.89 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: INFOSYS and SUN PHARMACEUTICAL IND L.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.